Analyst Ratings February 11, 2026

Goldman Keeps Neutral on Gilead After Strong Q4; Stock Near Yearly High

Gilead posts better-than-expected quarterly results and issues FY2026 guidance that emphasizes HIV growth amid headwinds

By Derek Hwang GILD
Goldman Keeps Neutral on Gilead After Strong Q4; Stock Near Yearly High
GILD

Goldman Sachs reiterated a Neutral rating and a $125 price target on Gilead Sciences after the company's fourth-quarter results. Gilead reported non-GAAP EPS of $1.86 and revenue of $7.93 billion, driven by HIV and oncology sales, and issued initial fiscal 2026 guidance calling for HIV growth and a decline in cell therapy.

Key Points

  • Goldman Sachs reaffirmed a Neutral rating and a $125 price target on Gilead Sciences after Q4 results; the stock was trading at $153.16, near its 52-week high.
  • Gilead reported non-GAAP EPS of $1.86 and revenue of $7.93 billion, with HIV and oncology sales cited as key drivers of the outperformance.
  • Fiscal 2026 guidance calls for 6% year-over-year growth in HIV despite about 2% policy-related headwinds, and projects a 10% decline in cell therapy due to competitive pressure.

Goldman Sachs has reaffirmed a Neutral rating on Gilead Sciences (NASDAQ:GILD) and kept its price target at $125 following the company’s fourth-quarter financial report. The stock was trading at $153.16, a level noted to be near its 52-week high of $153.13, and InvestingPro data categorized the shares as fairly valued based on its Fair Value assessment.

Gilead’s reported non-GAAP earnings per share for the quarter were $1.86, slightly ahead of consensus estimates of $1.81. Revenue in the quarter totaled $7.93 billion, above analysts’ expectations of $7.69 billion. The company attributed the stronger-than-anticipated results in part to elevated sales in its HIV and oncology franchises.

On a corporate scale, Gilead carries a market capitalization of $189.8 billion and continues to register strong financial metrics, reflected in an InvestingPro overall financial health score labeled as "GREAT."


Guidance and product-level outlook

Along with quarterly results, Gilead released its initial guidance for fiscal year 2026. The company expects the HIV segment to grow by 6% year over year, a projection that assumes roughly 2% of policy-related headwinds. In contrast, management forecast a 10% decline in the cell therapy business, attributing the drop to ongoing competitive pressures.

Gilead provided specific expectations for Yeztugo, projecting roughly $800 million in sales for the product. That figure sits below the consensus estimate of $922 million. Management said the Yeztugo outlook reflects anticipated steady growth in new patient starts and noted that the product currently has about 90% coverage, while also taking a conservative view on patient adherence.


Pipeline milestones and business development

Goldman Sachs highlighted several near-term milestones that investors will be watching. These include initial Phase 3 data for a weekly oral HIV treatment developed in partnership with Merck, expected in the first half of 2026, and plans to launch anito-cel for multiple myeloma in the second half of 2026. The bank also cited Gilead’s continued business development activities as a material element of the company’s outlook.


Market reaction and analyst commentary

Gilead’s fourth-quarter financials also outpaced some Wall Street expectations in separate reporting. The company reported EPS of $1.86, marginally above an alternate consensus figure of $1.85, and revenue of $7.93 billion versus another consensus estimate of $7.68 billion. Robust HIV sales underpinned an 8% increase in total product sales quarter over quarter and a 5% year-over-year gain.

Several analysts adjusted their price targets after the results. Needham raised its target to $170, pointing to the strength in HIV sales. BofA Securities moved its price target to $162, noting that product revenues beat consensus by about 4%. BMO Capital increased its target to $160 and emphasized the central role of the HIV franchise in Gilead’s investment case. These revisions indicate positive sentiment among some sell-side analysts in response to the quarterly performance.


Overall, the quarter delivered a mix of stronger-than-expected results and forward-looking guidance that balances growth in core HIV products against headwinds in cell therapy and conservatism around Yeztugo uptake. Investors and market participants will likely monitor upcoming clinical readouts and the planned launch of anito-cel as near-term catalysts for the stock.

Risks

  • Policy-related headwinds of approximately 2% could constrain HIV segment growth - this impacts the healthcare and biopharmaceutical sectors.
  • Continued competitive pressure is expected to drive a 10% decline in the cell therapy business, posing risks to the oncology and cell-therapy market segments.
  • Yeztugo sales are forecast at about $800 million, below the $922 million consensus, and management remains conservative around patient adherence, which could weigh on product revenue expectations in the pharmaceutical sector.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026